全球增生性糖尿病视网膜病变市场规模、份额、趋势和成长分析报告（2026-2034年）

预计增殖性糖尿病视网膜病变市场将从 2025 年的 38.9 亿美元成长到 2034 年的 82.1 亿美元，2026 年至 2034 年的复合年增长率为 8.66%。

随着全球糖尿病及其併发症的增加，增殖性糖尿病视网膜病变（PDR）市场正稳定成长。增殖性糖尿病视网膜病变（PDR）是严重的眼科疾病，如不及时治疗可导致视力丧失。人们对糖尿病眼疾筛检的认识不断提高，以及视网膜影像技术的进步，都促进了早期发现和治疗。开发中国家医疗保健服务的普及也推动了市场成长。

关键驱动因素包括抗VEGF疗法、雷射光凝术和玻璃体切除术的日益普及。药物创新和临床研究正在提高治疗效果和患者预后。此外，筛检计画的改进和远距眼科服务的普及使得及时诊断成为可能，尤其是在偏远地区。糖尿病患者数量的不断增长，尤其是在亚太地区和北美地区，显着支撑了对增殖性糖尿病视网膜病变（PDR）治疗方案的持续需求。

生物製药、缓释药物传递系统和基因疗法的进步为未来带来了广阔的前景。人工智慧驱动的视网膜筛检工具有望提高诊断效率。针对糖尿病管理的公共卫生措施的不断加强将进一步扩大治疗范围。随着早期疗育的普及，增殖性糖尿病视网膜病变市场预计将在未来几年保持稳定成长。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球增殖性糖尿病视网膜病变市场：依药物类别划分

• 市场分析、洞察与预测
• 抗 VEGF 药物
• 皮质类固醇

第五章：增殖性糖尿病视网膜病变全球市场：依给药途径划分

• 市场分析、洞察与预测
• 注射药物
• 口服
• 其他的

第六章：全球增殖性糖尿病视网膜病变市场：依通路划分

• 市场分析、洞察与预测
• 医院药房
• 零售药房
• 网路药房

第七章 全球增殖性糖尿病视网膜病变市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第八章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第九章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Genentech Inc
  • Novartis AG
  • Regeneron Pharmaceuticals Inc
  • Pfizer Inc
  • Merck KGaA
  • Cipla Inc
  • AbbVie Inc
  • Bausch Health Companies Inc
  • Santen Pharmaceutical Co. Ltd
  • Alimera Sciences
  • Intas Pharmaceuticals Ltd

The Proliferative Diabetic Retinopathy Market size is expected to reach USD 8.21 Billion in 2034 from USD 3.89 Billion (2025) growing at a CAGR of 8.66% during 2026-2034.

The Global Proliferative Diabetic Retinopathy Market is growing steadily due to the increasing global burden of diabetes and related complications. Proliferative diabetic retinopathy (PDR) is a severe eye condition that can lead to vision loss if untreated. Rising awareness regarding diabetic eye screening and advancements in retinal imaging technologies are supporting early detection and treatment. Expanding healthcare access in developing economies is also contributing to market growth.

Major drivers include the increasing adoption of anti-VEGF therapies, laser photocoagulation procedures, and vitrectomy surgeries. Pharmaceutical innovation and clinical research are enhancing treatment effectiveness and patient outcomes. Additionally, improved screening programs and tele-ophthalmology services are enabling timely diagnosis, particularly in remote areas. The growing diabetic population, especially in Asia-Pacific and North America, significantly supports sustained demand for PDR treatment solutions.

Future prospects appear promising with advancements in biologics, sustained-release drug delivery systems, and gene-based therapies. Artificial intelligence-assisted retinal screening tools are expected to improve diagnostic efficiency. Increasing public health initiatives targeting diabetes management will further expand treatment coverage. As early intervention becomes more accessible, the proliferative diabetic retinopathy market is projected to maintain steady growth over the coming years.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

• Anti-VEGF Agents
• Corticosteroids

By Mode of Administration

• Injectable
• Oral
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Genentech Inc, Novartis AG, Regeneron Pharmaceuticals Inc, Pfizer Inc, Merck KGaA, Cipla Inc, AbbVie Inc, Bausch Health Companies Inc, Santen Pharmaceutical Co Ltd, Alimera Sciences, Intas Pharmaceuticals Ltd
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PROLIFERATIVE DIABETIC RETINOPATHY MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. Anti-VEGF Agents Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Corticosteroids Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PROLIFERATIVE DIABETIC RETINOPATHY MARKET: BY MODE OF ADMINISTRATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Mode Of Administration
• 5.2. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PROLIFERATIVE DIABETIC RETINOPATHY MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PROLIFERATIVE DIABETIC RETINOPATHY MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Drug Class
  • 7.2.2 By Mode Of Administration
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Drug Class
  • 7.3.2 By Mode Of Administration
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Drug Class
  • 7.4.2 By Mode Of Administration
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Drug Class
  • 7.5.2 By Mode Of Administration
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Drug Class
  • 7.6.2 By Mode Of Administration
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL PROLIFERATIVE DIABETIC RETINOPATHY INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Genentech Inc
  • 9.2.2 Novartis AG
  • 9.2.3 Regeneron Pharmaceuticals Inc
  • 9.2.4 Pfizer Inc
  • 9.2.5 Merck KGaA
  • 9.2.6 Cipla Inc
  • 9.2.7 AbbVie Inc
  • 9.2.8 Bausch Health Companies Inc
  • 9.2.9 Santen Pharmaceutical Co. Ltd
  • 9.2.10 Alimera Sciences
  • 9.2.11 Intas Pharmaceuticals Ltd